Rockefeller Capital Management
ANIK icon

Rockefeller Capital Management’s Anika Therapeutics ANIK Stock Holding History

Rockefeller Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Buy
1,072
+858
+401% +$9.96K ﹤0.01% 3808
2025
Q4 		$2.06K Buy
+214
New +$2.05K ﹤0.01% 4309
2023
Q1 		– Sell
-13
Closed – – 2061
2022
Q4 		$0 Hold
13
– – ﹤0.01% 3831
2022
Q3 		$0 Sell
13
-18
-58% -$414 ﹤0.01% 3861
2022
Q2 		$0 Buy
+31
New +$692 ﹤0.01% 4085
2020
Q2 		– Sell
-1,000
Closed -$29K – 2569
2020
Q1 		$29K Buy
+1,000
New +$40.5K ﹤0.01% 1395
2019
Q4 		– Sell
-216
Closed -$12K – 2039
2019
Q3 		$12K Hold
216
– – ﹤0.01% 1359
2019
Q2 		$9K Buy
+216
New +$7.88K ﹤0.01% 1262

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Rockefeller Capital Management's ANIK Position: Q1 2026 in Review

Rockefeller Capital Management increased its Anika Therapeutics (ANIK) stake by 401% in Q1 2026, buying an estimated $9.96K and bringing the position to 1,072 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3808.

Rockefeller Capital Management first reported a position in ANIK in Q2 2019 and has held it in 8 quarters since. The position peaked at $29K in Q1 2020. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Rockefeller Capital Management held 1,072 shares of Anika Therapeutics worth $15.5K as of Q1 2026.
  • Rockefeller Capital Management bought 858 Anika Therapeutics shares in Q1 2026, an estimated $9.96K.
  • Anika Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3808 holding.
  • Rockefeller Capital Management first reported a position in Anika Therapeutics in Q2 2019 and has held it in 8 quarters since.
  • Rockefeller Capital Management's Anika Therapeutics position peaked at $29K in Q1 2020.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.